Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake.

Hematological toxicity Meta-iodobenzylguanidine (MIBG) Platelets Selective serotonin reuptake inhibitor (SSRI) Thrombocytopenia

Journal

EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946

Informations de publication

Date de publication:
08 Jul 2020
Historique:
received: 02 01 2020
accepted: 25 06 2020
entrez: 10 7 2020
pubmed: 10 7 2020
medline: 10 7 2020
Statut: epublish

Résumé

The therapeutic use of [ To determine the transport kinetics of SERT for [ SERT performed as a low-affinity transporter of [ Our study demonstrates for the first time that SSRIs selectively inhibit MIBG uptake in platelets without affecting MIBG accumulation in an in vivo neuroblastoma model. The concomitant application of citalopram during [

Sections du résumé

BACKGROUND BACKGROUND
The therapeutic use of [
METHODS METHODS
To determine the transport kinetics of SERT for [
RESULTS RESULTS
SERT performed as a low-affinity transporter of [
CONCLUSION CONCLUSIONS
Our study demonstrates for the first time that SSRIs selectively inhibit MIBG uptake in platelets without affecting MIBG accumulation in an in vivo neuroblastoma model. The concomitant application of citalopram during [

Identifiants

pubmed: 32642907
doi: 10.1186/s13550-020-00662-w
pii: 10.1186/s13550-020-00662-w
pmc: PMC7343696
doi:

Types de publication

Journal Article

Langues

eng

Pagination

78

Subventions

Organisme : Foundation for Pediatric Cancer Research
ID : No 93-011
Organisme : Dutch Cancer Society
ID : NKI 94-084
Organisme : European Community
ID : BMH4-CT98-3297

Références

Acta Psychiatr Scand. 1980 Mar;61(S280):97-110
pubmed: 28678363
Eur J Clin Pharmacol. 1985;28(5):553-7
pubmed: 3899675
Pediatr Blood Cancer. 2015 Jan;62(1):5-11
pubmed: 25175627
J Clin Oncol. 1998 Jan;16(1):229-36
pubmed: 9440747
Am J Pathol. 2006 Sep;169(3):861-76
pubmed: 16936262
Ann Emerg Med. 1999 Apr;33(4):457-9
pubmed: 10092727
Clin Pharmacokinet. 1993 Mar;24(3):203-20
pubmed: 8384945
Br J Radiol. 1994 Jun;67(798):573-8
pubmed: 8032811
Exp Hematol. 2002 Jun;30(6):555-63
pubmed: 12063022
Br J Pharmacol. 2017 Dec;174 Suppl 1:S360-S446
pubmed: 29055035
N Engl J Med. 2010 Jun 10;362(23):2202-11
pubmed: 20558371
J Clin Oncol. 2004 Jun 15;22(12):2452-60
pubmed: 15197208
Eur J Cancer. 1995;31A(4):603-6
pubmed: 7576978
Clin Ther. 2000 Dec;22(12):1525-32
pubmed: 11192143
J Nucl Med. 2018 Jul;59(7):1099-1103
pubmed: 29496989
J Hepatol. 2008 Apr;48(4):666-75
pubmed: 18280000
ACS Chem Neurosci. 2017 May 17;8(5):1011-1018
pubmed: 27959497
Clin Nucl Med. 1996 Dec;21(12):950-2
pubmed: 8957609
Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58
pubmed: 9537821
J Clin Oncol. 1994 Aug;12(8):1561-71
pubmed: 8040668
Pediatr Blood Cancer. 2009 Jul;52(7):784-90
pubmed: 19185008
Br J Pharmacol. 2009 Dec;158(7):1848-56
pubmed: 19912224
Psychoneuroendocrinology. 2001 May;26(4):433-9
pubmed: 11259862
J Nucl Med. 1990 Sep;31(9):1479-85
pubmed: 2395016
Drugs Aging. 1993 May-Jun;3(3):278-99
pubmed: 8324301
Eur J Pharmacol. 1983 Dec 23;96(3-4):303-9
pubmed: 6233162
Drugs. 1991 Mar;41(3):450-77
pubmed: 1711447
Int J Cancer. 1993 May 8;54(2):290-5
pubmed: 8486431
Int J Cancer. 2000 Dec 20;90(6):312-25
pubmed: 11180134
Pediatr Blood Cancer. 2016 Mar;63(3):436-42
pubmed: 26506090
Int Clin Psychopharmacol. 1994 Mar;9 Suppl 1:19-26
pubmed: 8021435
Int J Cancer. 1991 Jun 19;48(4):609-15
pubmed: 2045205
Science. 1991 Oct 25;254(5031):579-80
pubmed: 1948036
Sci Rep. 2018 Feb 22;8(1):3494
pubmed: 29472624
Nat Rev Dis Primers. 2016 Nov 10;2:16078
pubmed: 27830764
Cell Tissue Res. 2011 Nov;346(2):151-61
pubmed: 22006250
Int J Cancer. 2000 Aug 1;87(3):412-22
pubmed: 10897048
Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2542-6
pubmed: 7681602
Neurochem Res. 2010 Apr;35(4):628-35
pubmed: 20041293
J Nucl Med. 2001 Nov;42(11):1713-21
pubmed: 11696644
J Clin Oncol. 1996 Jun;14(6):1787-97
pubmed: 8656247
Eur J Nucl Med. 1994 Jan;21(1):46-52
pubmed: 8088285
Pharmacol Ther. 2000 Jan;85(1):11-28
pubmed: 10674711
Int J Clin Pharmacol Ther. 2007 May;45(5):300-6
pubmed: 17542353
Prog Clin Biol Res. 1988;271:679-87
pubmed: 3406024
Braz J Med Biol Res. 2014 Jul;47(7):554-9
pubmed: 25003632
Clin Pharmacokinet. 1994 Sep;27(3):175-90
pubmed: 7988100
Ann N Y Acad Sci. 1990;600:68-78; discussion 79-80
pubmed: 2252338
Blood. 2012 Apr 12;119(15):3394-402
pubmed: 22337717
Med Pediatr Oncol. 1987;15(4):199-202
pubmed: 3309604
Eur J Pharmacol. 1984 Sep 17;104(3-4):277-86
pubmed: 6499924
Thromb Res. 2010 Aug;126(2):e83-7
pubmed: 20553948

Auteurs

Thomas Blom (T)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Gastroenterology & Metabolism, Department of Clinical Chemistry, Amsterdam University Medical Center, Amsterdam, The Netherlands.

Rutger Meinsma (R)

Gastroenterology & Metabolism, Department of Clinical Chemistry, Amsterdam University Medical Center, Amsterdam, The Netherlands.

Marja Rutgers (M)

Department of Experimental Therapy, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Corine Buitenhuis (C)

Department of Experimental Therapy, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Marieke Dekken-Van den Burg (M)

Department of Pediatric Oncology, Emma Children's Hospital, Amsterdam University Medical Center, Amsterdam, The Netherlands.

André B P van Kuilenburg (ABP)

Gastroenterology & Metabolism, Department of Clinical Chemistry, Amsterdam University Medical Center, Amsterdam, The Netherlands.

Godelieve A M Tytgat (GAM)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. g.a.m.tytgat@prinsesmaximacentrum.nl.

Classifications MeSH